Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
2024 · Nature · 280 citations
https://doi.org/10.1038/s41586-024-07205-6
J
Julien Dilly
Broad Institute(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
229
Papers
907
Citations
10
h-index
10
i10-index
Julien Dilly is an academic researcher from Broad Institute. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Cancer Genomics and Diagnostics & Colorectal Cancer Treatments and Studies. The author has an h-index of 10, co-authored 195 publications.
ORCID: 0000-0002-4006-5285Papers by this author
worksMechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2024 · Cancer Discovery · 196 citations
https://doi.org/10.1158/2159-8290.cd-24-0177
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
2024 · Nature · 157 citations
https://doi.org/10.1038/s41586-024-07379-z
A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumors
2025 · Science · 22 citations
https://doi.org/10.1126/science.ads0239
Integrative genomic identification of therapeutic targets for pancreatic cancer
2025 · Cell Reports · 3 citations
https://doi.org/10.1016/j.celrep.2025.116191
Supplementary Table S9 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27033367
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat